Literature DB >> 27471626

Predictive immune markers in advanced melanoma patients treated with ipilimumab.

Viktor Umansky1, Jochen Utikal1, Christoffer Gebhardt1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.

Entities:  

Keywords:  Eosinophils; HMGB1; S100A8/A9; ipilimumab; melanoma; myeloid-derived suppressor cells; predictive markers

Year:  2016        PMID： 27471626      PMCID： PMC4938357          DOI： 10.1080/2162402X.2016.1158901

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation.

Authors:  Peter Altevogt; Niko P Bretz; Johannes Ridinger; Jochen Utikal; Viktor Umansky
Journal:  Semin Cancer Biol       Date:  2014-04-24       Impact factor: 15.707

Review 2.  Myeloid-derived suppressor cells in malignant melanoma.

Authors:  Viktor Umansky; Alexandra Sevko; Christoffer Gebhardt; Jochen Utikal
Journal:  J Dtsch Dermatol Ges       Date:  2014-09-28       Impact factor: 5.584

Review 3.  New insights into chronic inflammation-induced immunosuppression.

Authors:  Julia Kanterman; Moshe Sade-Feldman; Michal Baniyash
Journal:  Semin Cancer Biol       Date:  2012-02-24       Impact factor: 15.707

Review 4.  Coordinated regulation of myeloid cells by tumours.

Authors:  Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 5.  Melanoma-induced immunosuppression and its neutralization.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Semin Cancer Biol       Date:  2012-02-13       Impact factor: 15.707

Review 6.  New therapeutic options for advanced non-resectable malignant melanoma.

Authors:  Simone Stadler; Kasia Weina; Christoffer Gebhardt; Jochen Utikal
Journal:  Adv Med Sci       Date:  2014-12-25       Impact factor: 3.287

7.  Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.

Authors:  Huanhuan Jiang; Christoffer Gebhardt; Ludmila Umansky; Philipp Beckhove; Torsten J Schulze; Jochen Utikal; Viktor Umansky
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

8.  Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Authors:  Christoffer Gebhardt; Alexandra Sevko; Huanhuan Jiang; Ramtin Lichtenberger; Maike Reith; Kathrin Tarnanidis; Tim Holland-Letz; Ludmila Umansky; Philipp Beckhove; Antje Sucker; Dirk Schadendorf; Jochen Utikal; Viktor Umansky
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

Review 9.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.

Authors:  Muhammad Zaeem Noman; Giacomo Desantis; Bassam Janji; Meriem Hasmim; Saoussen Karray; Philippe Dessen; Vincenzo Bronte; Salem Chouaib
Journal:  J Exp Med       Date:  2014-04-28       Impact factor: 14.307
  10 in total
  12 in total

Review 1.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 2.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

3.  Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.

Authors:  V Damuzzo; S Solito; L Pinton; E Carrozzo; S Valpione; J Pigozzo; R Arboretti Giancristofaro; V Chiarion-Sileni; S Mandruzzato
Journal:  Oncoimmunology       Date:  2016-11-01       Impact factor: 8.110

4.  SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells.

Authors:  Priscilla S Redd; Mohammed L Ibrahim; John D Klement; Sarah K Sharman; Amy V Paschall; Dafeng Yang; Asha Nayak-Kapoor; Kebin Liu
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

Review 5.  Intercellular crosstalk in human malignant melanoma.

Authors:  Barbora Dvořánková; Pavol Szabo; Ondřej Kodet; Hynek Strnad; Michal Kolář; Lukáš Lacina; Eliška Krejčí; Ondřej Naňka; Aleksi Šedo; Karel Smetana
Journal:  Protoplasma       Date:  2016-11-03       Impact factor: 3.356

6.  Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy.

Authors:  Saurabh K Garg; Matthew J Ott; A G M Mostofa; Zhihua Chen; Y Ann Chen; Jodi Kroeger; Biwei Cao; Adam W Mailloux; Alisha Agrawal; Braydon J Schaible; Amod Sarnaik; Jeffrey S Weber; Anders E Berglund; James J Mulé; Joseph Markowitz
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

7.  Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

Authors:  Quentin Scanvion; Johana Béné; Sophie Gautier; Aurélie Grandvuillemin; Christine Le Beller; Chouki Chenaf; Nicolas Etienne; Solenn Brousseau; Alexis B Cortot; Laurent Mortier; Delphine Staumont-Sallé; Franck Morschhauser; Alexandra Forestier; Matthieu Groh; David Launay; Eric Hachulla; Myriam Labalette; Jean-Emmanuel Kahn; Guillaume Lefèvre
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

8.  Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy.

Authors:  Jia-Nan Cheng; Wen Luo; Chengdu Sun; Zheng Jin; Xianghua Zeng; Peter B Alexander; Zhihua Gong; Xin Xia; Xiaofang Ding; Shouxia Xu; Ping Zou; Yisong Y Wan; Qingzhu Jia; Qi-Jing Li; Bo Zhu
Journal:  Sci Adv       Date:  2021-01-29       Impact factor: 14.136

9.  Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.

Authors:  Tressie Herrmann; Angeline Ginzac; Ioana Molnar; Sébastien Bailly; Xavier Durando; Hakim Mahammedi
Journal:  Cancer Med       Date:  2021-08-18       Impact factor: 4.452

10.  Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Authors:  Sonja I Buschow; Matteo Ramazzotti; Gerold Schuler; Duccio Cavalieri; Carl G Figdor; Inge M J Reinieren-Beeren; Lucie M Heinzerling; Harm Westdorp; Irene Stefanini; Luca Beltrame; Stanleyson V Hato; Eva Ellebaek; Stefanie Gross; Van Anh Nguyen; Georg Weinlich; Jiannis Ragoussis; Dilair Baban; Beatrice Schuler-Thurner; Inge M Svane; Nikolaus Romani; Jonathan M Austyn; I Jolanda M De Vries
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.